Skip to main content
. 2014 Dec 10;2(4):841–853. doi: 10.3390/vaccines2040841

Figure 2.

Figure 2

Administration of activating anti-CD137 antibody preferentially enhances the effects of cisplatin treatment. Tumor growth curves (for individual mice) and group Kaplan-Meyer survival curves are shown for mice receiving cisplatin or radiation with IgG, and for mice receiving cisplatin or radiation in conjunction with activating anti-CD137 antibody. (A) Growth curves of mice receiving three doses of radiation (8 Gy, on indicated days, arrows) and control IgG (on indicated days, asterisks); (B) Growth curves of mice receiving three doses of radiation (arrows) and anti-CD137 antibody (asterisks); (C) Kaplan-Meyer survival plot comparing mice in A and B; (D) Growth curves of mice receiving three doses of cisplatin (20 mg/kg, on indicated days, arrows) and control IgG (on indicated days, asterisks); (E) Growth curves of mice receiving cisplatin (arrows) together with anti-CD137 antibody (asterisks); (F) Kaplan-Meyer survival plots of groups in D and E.